ProCE Banner Activity

A Year in Review: ADCs Targeting HER3 in NSCLC

Slideset

Gain expert insights with these downloadable slides featuring key data on HER3-directed antibody–drug conjugates and implications for management of advanced EGFR-mutated NSCLC with resistance to EGFR TKI therapy.

Released: January 29, 2024

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.